Combined chemotherapy and radiotherapy, followed or not by surgery, in squamous cell carcinoma of the esophagus

Détails

ID Serval
serval:BIB_928F8ECDEFF7
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Combined chemotherapy and radiotherapy, followed or not by surgery, in squamous cell carcinoma of the esophagus
Périodique
Annals of Oncology
Auteur(s)
de Pree  C., Aapro  M. S., Spiliopoulos  A., Popowski  Y., Mermillod  B., Mirimanoff  R. O., Alberto  P.
ISSN
0923-7534 (Print)
Statut éditorial
Publié
Date de publication
07/1995
Volume
6
Numéro
6
Pages
551-7
Notes
Clinical Trial
Journal Article --- Old month value: Jul
Résumé
BACKGROUND: This study was designed to evaluate the feasibility of a neo-adjuvant combined chemo-radiotherapy in patients with localized squamous cell carcinoma of the esophagus. PATIENTS AND METHODS: Forty-two patients with squamous cell carcinoma of the esophagus, stages II and III (or stage I if considered to be poor candidates for immediate curative surgery), age less than 70 years and WHO performance status 0 to 2, were enrolled in a study of radiotherapy combined with chemotherapy, consisting of 2 (operated patients) or 3 (nonoperated patients) courses of cisplatin, vindesine, mitomycin-C or cisplatin, vinblastine. Surgery was routinely proposed to patients. RESULTS: Thirty-seven patients (88%) received full preoperative therapy. Of 30 patients responding to this preoperative therapy, 12 had a third cycle of treatment and 15 had esophagectomy. Three of the operated patients had no pathological evidence of residual tumour. Median survival of all 42 patients is 11 months and the 2-year survival rate is 29%. There is no difference in survival among responding operated or non-operated patients. Our group represents 95% of all eligible cases of squamous cell carcinoma of the esophagus occurring in Geneva during the study period. CONCLUSION: Our series gives a realistic view of the median survival of a population of patients eligible for neo-adjuvant therapy of esophagus cancer, and suggests that secondary surgery might not improve the patient survival. Furthermore, non-selected patients are at high risk for therapy-related death.
Mots-clé
Adult Aged Analysis of Variance Antineoplastic Combined Chemotherapy Protocols/therapeutic use Carcinoma, Squamous Cell/drug therapy/radiotherapy/surgery/*therapy Combined Modality Therapy Esophageal Neoplasms/drug therapy/radiotherapy/surgery/*therapy Esophagectomy Female Humans Male Middle Aged Prognosis Proportional Hazards Models Radiotherapy Dosage Survival Rate Treatment Outcome
Pubmed
Web of science
Création de la notice
24/01/2008 18:12
Dernière modification de la notice
03/03/2018 19:32
Données d'usage